Apparently, EPO has an angiogenic effect, a half-life of 4-9 hours when ad ministered IV and 18-24 hours if administered subcutaneously.
Con ello aumenta la resistencia a la hipoxia celular protegiendo los tejidos ante la isquemia. Al parecer, posee efecto angiogénico.